Molecular Research on Biomarker and Proteomics Analysis
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (5 February 2024) | Viewed by 1823
Special Issue Editor
Special Issue Information
Dear Colleagues,
Proteomics began in the mid-1990s, followed by metabolomics, which has emerged thereafter, and genomics, which is still evolving, and the technological development of these comprehensive analyses continues unabated. With such significant progress in the information obtained from omics, we have moved from the past era in which diseases were classified based on patients' own complaints, physicians' observations, anatomy, and histology, to an era in which diseases are determined at the molecular level, such as genes. With this shift, we are moving away from the one-size-fits-all approach of treating many people in the same way to an era of precision medicine that takes into account differences in individual genetic and environmental factors. In this precision medicine, precise diagnosis and clinical trials based on biomarkers are indispensable.
To study human diseases, it is direct to analyze human samples, not cells or animals. Tumor tissue is relatively easy to obtain for cancer, but for many diseases, such as hypertension and psychiatric disorders, the site of the lesion is not clear or difficult to obtain. Furthermore, biological samples that are difficult to obtain repeatedly, such as biopsies, are not suitable for studying changes over time. In other words, the availability of human samples is limited to blood, urine, etc. Therefore, disease-related biomarkers obtained from omics analysis conducted on disease model animals or cells should be measured in humans to verify hypotheses and lead to disease treatment or prevention, or biomarker measurement can be used as a diagnostic method.
This special issue discusses the latest research on how biomarker data can be applied to human patients and how to find appropriate biomarkers. Also includes research on MS analysis for multi-omics, development of basic MS techniques to facilitate biomarker determination, and new methods to improve MS data analysis.
Dr. Yoshiya Oda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarker
- proteomics
- genomics
- transcriptomics
- precision medicine
- multi-omics
- mass spectrometry analysis
